Combining genetic variations in CYP2C9 and VKORC1 with clinical factors for warfarin dosing determination improved clinical effectiveness.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Pharmacogenomics (London)

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/pgs.13.29PMID 23556443
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy

  2012cited by this paper
• CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.

  2012cited by this paper
• A Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing (CoumaGen-II)

  2012cited by this paper
• Use of the MLPA Assay in the Molecular Diagnosis of Gene Copy Number Alterations in Human Genetic Diseases

  2012cited by this paper
• Similarity in recombination rate and linkage disequilibrium at CYP2C and CYP2D cytochrome P450 gene regions among Europeans indicates signs of selection and no advantage of using tagSNPs in population isolates

  2012cited by this paper
• Copy number variants in pharmacogenetic genes.

  2011cited by this paper
• Genetics InFormatics Trial (GIFT) of Warfarin to Prevent Deep Vein Thrombosis (DVT): Rationale and Study Design

  2011cited by this paper
• Statistical design of personalized medicine interventions: The Clarification of Optimal Anticoagulation through Genetics (COAG) trial

  2010cited by this paper
• Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.

  2009cited by this paper
• A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose

  2009cited by this paper
• Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.

  2009cited by this paper
• Estimation of the warfarin dose with clinical and pharmacogenetic data.

  2009cited by this paper
• A genome-wide association study of acenocoumarol maintenance dosage.

  2009cited by this paper
• Pharmacogenomics--ready for prime time?

  2008cited by this paper
• A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.

  2008cited by this paper
• Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.

  2008cited by this paper
• Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.

  2008cited by this paper
• An Evaluation of the Performance of Tag SNPs Derived from HapMap in a Caucasian Population

  2006cited by this paper
• The Human Cytochrome P450 Allele Nomenclature Committee Web Site : Submission Criteria, Procedures, and Objectives.

  2006cited by this paper
• CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

  2005cited by this paper
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

  2005cited by this paper
• A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

  2005cited by this paper
• Genomic Disorders: Molecular Mechanisms for Rearrangements and Conveyed Phenotypes

  2005cited by this paper
• The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.

  2005cited by this paper
• A comparison of linkage disequilibrium patterns and estimated population recombination rates across multiple populations.

  2005cited by this paper
• A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

  2005cited by this paper
• Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen

  2004cited by this paper
• Detection of large-scale variation in the human genome

  2004cited by this paper
• Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification.

  2002cited by this paper
• Use of population isolates for mapping complex traits

  2000cited by this paper
• Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.

  1999cited by this paper
• Metabolites of tamoxifen in animals and man: Identification, pharmacology, and significance

  1982cited by this paper

• Gene polymorphisms and contents of cytochrome P450s have only limited effects on metabolic activities in human liver microsomes.

  2016cites this paper
• Quality control metrics improve repeatability and reproducibility of single-nucleotide variants derived from whole-genome sequencing

  2014cites this paper